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Abstract In this issue of the journal, Erqou and colleagues
(DOI 10.1007/s00125-014-3374-x) report, in a systematic
review and meta-analysis of randomised trials, a very modest
(1.3 mmol/mol or 0.12%) albeit significant increase in HbA1c
in patients with diabetes treated with statins, compared with
control. Here, we discuss the clinical relevance of the findings.
Given the overwhelming benefit of statins on cardiovascular
outcomes in diabetes, current guidelines recommending
statins for primary prevention in type 2 diabetes should not
change, and any effect on microvascular risk is likely to be
minimal. Of course, all patients recommended for statin
treatment, whether they have diabetes or not, should now be
warned of a slight potential for dysglycaemia on starting
statins, but at the same time they should be told that very
modest lifestyle improvement will help offset this
dysglycaemia risk. Finally, we remind colleagues that nearly
all drugs have side effects and we should not be surprised by
this statin–dysglycaemia effect, which can be easily managed.
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The increased risk of new-onset type 2 diabetes associated
with statin treatment is now well established. Large meta-
analyses of randomised controlled trials (RCTs) of statins
have demonstrated increased risk of developing type 2 diabe-
tes when statins are compared with placebo or standard care
[1], and when more intensive statin treatment is compared
with less intensive [2]. Observational studies have also
reported similar findings [3–5], although their design prevents
inference of a causal role for statins. Nonetheless, one must
remember that statins confer a substantial reduction in risk of
cardiovascular disease (CVD) events in patients with and
without established diabetes [6–8], so that the magnitude of
CVD risk reduction for those eligible for statin treatment
easily trumps any small increase in diabetes risk.
Nonetheless, there is now widespread interest in the nature
of the relationship between statins and diabetes. Although
RCT evidence suggests the effect is a consequence of statin
treatment per se, observational studies have offered widely
varying estimates of the magnitude of the association [3–5],
and there has been uncertainty as regards the underlying
biological mechanism [9]. A recent analysis of RCTs and
genetic studies proposes a mechanistic link between statins
and diabetes. Both statin treatment and variants in the gene
encoding 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase
(HMGCR), the intended chemical target of statins, are associ-
ated with higher body weight and higher type 2 diabetes risk
[10]. This consequence of statin treatment appears to be both
on-target (i.e. mediated through HMG-CoA reductase inhibi-
tion) and, since higher body weight is known to be a causal
factor in the development of diabetes [11], is likely to contrib-
ute at least in part to its diabetogenic effect.
Despite the growing body of evidence investigating the
link between statins and new-onset diabetes, their effect on
glycaemia in people with existing diabetes has attracted rela-
tively limited consideration, with little published on the sub-
ject. In this issue of Diabetologia, Erqou and colleagues
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present evidence for a dysglycaemic effect of statins in indi-
viduals with diabetes [12], helping to fill this gap in the
literature. The issue is an important one: diabetes is a well-
established risk factor for CVD [13], and patients with diabe-
tes are treated earlier and more intensively with statins than
non-diabetic individuals are. Indeed, although the National
Institute for Health and Care Excellence (NICE) has recently
advised the reintroduction of risk scoring in type 2 diabetes,
with statins recommended when the 10-year CVD risk is
≥10% [14], most countries adopt a 'fire and forget' approach,
with all type 2 diabetic patients aged over 40 years offered
statins [15], a position recently reiterated by the Joint British
Societies (JBS)3 guidelines [16]. As statins are consequently
prescribed to the overwhelming majority of patients with type
2 diabetes, investigating the influences of statin treatment on
glycaemic control in these patients is merited.
The authors present a well-executed systematic review and
meta-analysis of published summary-level results of statin
trials that reported pre- and post-treatment HbA1c. The trials
were largely conducted in patients with type 2 diabetes
(although a small number included patients with type 1
diabetes or mixed samples), and the participants were
characteristic of many patients being managed concurrently
in the clinic for type 2 diabetes and CVD risk. The
analyses included 9,696 individuals from nine trials,
followed for an average of 3.6 years, and treated with a
range of dosages of atorvastatin, pravastatin and simvastat-
in. Statin treatment led to a modest (0.12%; 1.3 mmol/mol)
increase in HbA1c when compared with the control, a finding
that persisted in the type 2 diabetes-only subgroup, but was
null in the smaller subgroup of type 1 diabetes and mixed
populations. This study has a number of important strengths.
First, it is the first substantial demonstration of a dysglycaemic
effect of statin treatment among patients with existing diabe-
tes. Second, the findings add weight to the growing body of
evidence suggesting statin treatment is per se diabetogenic
across a range of patients. This study is lent particular impact
by its basis in randomised trials, enabling such causal
inference as pharmacoepidemiological studies are unable
to permit. Some weaknesses are also noteworthy. First,
the number of trials with available relevant data is relative-
ly small when compared with those used to quantify the
effect of statins on risk of new-onset type 2 diabetes [10],
and there was modest inter-study heterogeneity.
Unpublished data are not included, and it is possible that
these may harbour further helpful information; trial inves-
tigators should be motivated by this study to make such
data accessible so that a more robust conclusion can be
drawn. As the authors point out, data were unavailable on
participants’ use of hypoglycaemic medication, and the
range of statin drugs and dosages available was limited. It
is possible that, as dysglycaemia progressed in statin-treated
patients, their treating physicians may have intensified their
hypoglycaemic therapy, leading to an attenuation of the
observed statin–HbA1c effect.
If one accepts the HbA1c changes as real, the key question
raised by this study, and other recent related findings, concerns
its clinical implications, if any, for the care of patients with
diabetes. CVD remains the chief cause of mortality and major
morbidity among type 2 diabetic patients [13], and statins
have been shown beyond doubt to reduce risk of CVD events
in this population. Among type 2 diabetic patients, worsening
dysglycaemia (indicated by higher HbA1c) only modestly
raises risk of macrovascular disease such as myocardial
infarction and ischaemic stroke [17, 18], being of greater
relevance to microvasculature outcomes of nephropathy, reti-
nopathy and peripheral neuropathy [17]. Furthermore, in pa-
tients with good medium- to long-term glycaemic control
(HbA1c <7% or 53 mmol/mol), there appears to be only a
weak relationship between changes in HbA1c and CVD risk
[18]. The primary clinical value of statins lies in the preven-
tion of macrovascular disease, an effect that is not meaning-
fully diminished by a small disturbance of glycaemic control
(Fig. 1). There may, of course, be a very small effect on
microvascular risk, but this question will be difficult to exam-
ine at an acceptable level of statistical power with the currently
available trial data. The balance of benefit and risk falls,
therefore, strongly in favour of continuing to prescribe statins
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Fig. 1 The beneficial effects of lipid-lowering by statins greatly out-
weighs the adverse effects of increased glycaemia for risk of
macrovascular (atherosclerotic) disease. LDL-C, LDL-cholesterol
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for type 2 diabetic patients according to current guidelines. All
such guidelines highlight the importance of lifestyle modifi-
cation for the prevention of CVD and other diabetic compli-
cations. Evidence such as that presented by Erqou and col-
leagues for the adverse, but comparatively minor, effects of
statins on glycaemia should encourage healthcare profes-
sionals to redouble their efforts to help their patients to
improve their diets, engage in more physical activity and stop
smoking. Even small and sustainable lifestyle changes can not
only improve glycaemic control, but may also enhance
patients’ quality of life in a win–win scenario. We must
remember that few drugs lack adverse effects and that recent
reductions in type 2 diabetes CVD mortality have likely
largely resulted from improvements in cholesterol, blood
pressure and smoking behaviours, as recently reviewed [19].
Finally, this study raises a further important issue regarding
public and professional perceptions of statin drugs. Statins are
not the only class of drug used in CVD prevention that raises
plasma glucose concentration. Thiazide diuretics, for example,
are commonly prescribed to patients with diabetes and have
been shown to cause hyperglycaemia [20], but the spotlight of
negative publicity appears to have fallen disproportionately on
statins. This is likely because of the overwhelming frequency
with which statins are prescribed, and the growing concern
among patients and physicians about their other adverse effects.
The bad press seems imbalanced, however, given both the
considerable benefits for individual population health that these
drugs confer and their excellent safety record, particularly when
compared with other widely prescribed drugs such as aspirin.
As mentioned above, no drug can be entirely free of adverse
effects. However, the robustly demonstrated sizable benefits of
statin treatment with minimal concomitant harm, and improved
algorithms to handle statin intolerance [16] should remain
foremost in the minds of the clinician and the patient when
they are considering using a statin.
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